KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cost of Revenue: 2013-2024

Historic Cost of Revenue for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Dec 2024 value amounting to $77.9 million.

  • Supernus Pharmaceuticals' Cost of Revenue rose 7.86% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.7 million, marking a year-over-year increase of 8.70%. This contributed to the annual value of $77.9 million for FY2024, which is 7.01% down from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Cost of Revenue is $77.9 million, which was down 7.01% from $83.8 million recorded in FY2023.
  • Supernus Pharmaceuticals' Cost of Revenue's 5-year high stood at $87.2 million during FY2022, with a 5-year trough of $52.5 million in FY2020.
  • Over the past 3 years, Supernus Pharmaceuticals' median Cost of Revenue value was $83.8 million (recorded in 2023), while the average stood at $83.0 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Cost of Revenue surged by 214.88% in 2020 and then fell by 7.01% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Cost of Revenue (Yearly) stood at $52.5 million in 2020, then surged by 43.09% to $75.1 million in 2021, then increased by 16.20% to $87.2 million in 2022, then declined by 3.95% to $83.8 million in 2023, then fell by 7.01% to $77.9 million in 2024.